Abstract
Our aim was to compare the analgesic efficacy of pamidronate (PAM) and synthetic human calcitonin (CT) in intravenous infusion for recent painful benign vertebral compression in a randomised prospective double-blind study. Twenty-seven patients aged 49–85 years with painful benign non-traumatic vertebral compression were included in the study. They received either PAM (1 mg/kg) or synthetic human CT (1.5 mg) as an intravenous infusion. Pain and functional disability were evaluated before infusion, and 4 and 30 days afterwards. The pain score assessed on a visual analogue scale at day 0 was 5.94±2.47 in patients treated with PAM and 6.27±2.50 in patients treated with CT (p=0.74); at day 4, 4.8±2.80 with PAM vs 3.9±2.68 with CT (p=0.37); and at day 30, 3.6±3.13 with PAM vs 3.10±2.76 with CT (p=0.70). Spinal function scores were 18.21±3.17 at day 0 in patients treated with PAM vs 17.23±4.42 in patients treated with CT (p=0.69) and at day 30, 13.7±5.36 with PAM vs 12.33±3.22 with CT (p=0.68). We found no advantage of PAM over CT in a single intravenous infusion for the treatment of painful recent benign vertebral compression. Since CT is ten times less costly, its use should be preferred.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melton LJ, Kan SH, Frye MA, Wahner HW, O’Fallon WM, Riggs BL (1989) Epidemiology of vertebral fractures in women. Am J Epidemiol 129:1000–1011
Blau LA, Hoehns JD (2003) Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 37:564–570
Hortobagyi GN, Thériault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785–1791
Pappagallo M, Breuer B, Schneider A, Sperber K (2003) Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 26:678–683
Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of a semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:626–637
Coste J, Le Parc JM, Berge E, Delecoeuillerie G, Paolaggi JB (1993) French validation of a disability rating scale for the evaluation of low back pain (EIFEL questionnaire). Rev Rhum 60:335–341 (article in French)
Silverman SL, Azria M (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858–867
Gennari C, Agnusdei D, Camporeale A (1991) Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49(Suppl 2):S9–S13
Maresca V (1985) Human calcitonin in the management of osteoporosis: a multicentre study. J Int Med Res 13:311–316
Wuster C, Schurr W, Scharla S, Raue F, Minne HW, Ziegler R (1991) Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers. Eur J Clin Pharmacol 41:211–215
Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertébra fractures: a double-blind-placebo controlled clinical study. Calcif Tissue Int 49(6):369–372
Paterson AH (1997) Should bisphosphonates be standard therapy for bone pain? Support Care Cancer 5:200–204
Gangji V, Appelboom T (1999) Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 18:266–267
Godfrin B, Alvarez M, Laroche M, Ollier S, Dingremont C, Sailler L, Arlet P (2000) Analgesic effect of a diphosphonate perfusion during the acute phase of vertebral compression in the elderly subject. Rev Med Interne 21:1004–1005
Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100
Coukell AJ, Markham A (1998) Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget’s disease of bone. Drugs Aging 12:149–168
Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(3 Suppl):185S–189S
Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103(2A):30S–43S
Ryan PJ, Blake G, Herd R, Fogelman I (1994) A clinical profile of back pain and disability in patients with spinal osteoporosis. Bone 15:27–30
Melton LJ (1997) Epidemiology of spinal osteoporosis. Spine 22(24 Suppl):2S–11S
Cortet B, Cotten A, Boutry N, Flipo RM, Duquesnoy B, Chastanet P, Delcambre B (1999) Percutaneous vertebroplasty in the treatment of osteoporotic vertebral compression fractures: an open prospective study. J Rheumatol 26:2222–2228
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laroche, M., Cantogrel, S., Jamard, B. et al. Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol 25, 683–686 (2006). https://doi.org/10.1007/s10067-005-0159-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0159-0